{"schema_version":"secwatch.filing_event.v1","accession":"0001720580-26-000036","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2026-05-13T20:04:12+00:00","discovered_at":"2026-05-13T20:05:00.468401+00:00","generated_at":"2026-05-13T22:15:21.578271+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adicet Bio Q1 net loss $20.2M; prula-cel Phase 1 data expected mid-2026","bullets":["Net loss $20.2M ($1.88/share) vs $28.2M ($4.96/share) in Q1 2025; R&D expenses down to $17.5M.","Cash, cash equivalents and ST investments $137.6M at March 31, 2026; expected runway into H2 2027.","Phase 1 prula-cel update in mid-2026 with at least 20 LN/SLE patients, min 6 months follow-up.","FDA interaction in Q2 2026 to inform potential pivotal trial design; plan to start pivotal program in H2 2026.","Regulatory filing for ADI-212 in mCRPC planned for Q3 2026; Phase 1 enrollment expected Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001720580-26-000036","json":"https://secwatch.observer/filing/0001720580-26-000036.json","markdown":"https://secwatch.observer/filing/0001720580-26-000036.md","text":"https://secwatch.observer/filing/0001720580-26-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000036/0001720580-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000036/acet-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T22:15:21.578271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}